Ptc Therapeutics (PTCT) EBIT (2012 - 2026)
Ptc Therapeutics (PTCT) posted quarterly EBIT of $149.0 million for Q2 2026, up 526.17% year-over-year from $23.8 million in Q2 2025, and up 231.36% quarter-over-quarter from $45.0 million in Q1 2026.
Ptc Therapeutics (PTCT) EBIT (2012 - 2026) Analysis & Trends
Ptc Therapeutics' EBIT history runs 15 years deep, the most recent figure standing at $149.0 million for Q2 2026.
- In Q2 2026, EBIT rose 526.17% year-over-year to $149.0 million; the TTM figure through Jun 2026 stood at $125.6 million (down 82.52% YoY), while the FY2025 annual figure was $866.9 million, up 386.52% from the prior year.
- EBIT for Q2 2026 stood at $149.0 million, up from $45.0 million in the prior quarter.
- The five-year high for EBIT was $970.2 million in Q1 2025, with the low at -$209.5 million in Q2 2023.
- The 5-year median for EBIT is -$61.3 million (2022), against an average of -$7.1 million.
- The sharpest annual moves came in 2024 and 2025: EBIT tumbled 2890.19% in 2024, then soared 2234.57% in 2025.
- Ptc Therapeutics' EBIT stood at -$200.3 million in 2022, then soared by 102.91% to $5.8 million in 2023, then sank by 2890.19% to -$162.4 million in 2024, then jumped by 56.06% to -$71.3 million in 2025, then jumped by 308.8% to $149.0 million in 2026.
- Business Quant data shows PTCT's EBIT at $149.0 million in Q2 2026, $45.0 million in Q1 2026, and -$71.3 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Ptc Therapeutics | 5.97 Bn | 3.75 Bn | 340.60 Mn | 148.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 148.98 Mn |
| Mar 31, 2026 | 44.96 Mn |
| Dec 31, 2025 | -71.35 Mn |
| Sep 30, 2025 | 3.02 Mn |
| Jun 30, 2025 | -34.96 Mn |
| Mar 31, 2025 | 970.23 Mn |
| Dec 31, 2024 | -162.39 Mn |
| Sep 30, 2024 | -54.51 Mn |
| Jun 30, 2024 | -40.22 Mn |
| Mar 31, 2024 | -45.45 Mn |
| Dec 31, 2023 | 5.82 Mn |
| Sep 30, 2023 | -118.16 Mn |
| Jun 30, 2023 | -209.54 Mn |
| Mar 31, 2023 | -117.62 Mn |
| Dec 31, 2022 | -200.34 Mn |
| Sep 30, 2022 | -68.19 Mn |
| Jun 30, 2022 | -92.36 Mn |
| Mar 31, 2022 | -86.52 Mn |
| Dec 31, 2021 | -84.73 Mn |
| Sep 30, 2021 | -93.08 Mn |